Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative therapies targeting challenging cancer pathways, particularly the RAS and mTOR signaling pathways. The company utilizes a unique approach that reconfigures natural substances into optimized drug candidates, building on the pioneering work of its founder, Martin D. Burke. Revolution Medicines has established an exclusive licensing agreement with the University of Illinois to utilize and further develop this transformative synthetic technology. Among its key product candidates are RMC-4630, a SHP2 inhibitor, and various programs within its RAS(ON) portfolio, along with SOS1 and 4EBP1/mTORC1 initiatives. The company's focus on harnessing complex natural products to create refined, effective therapies positions it to address significant unmet medical needs in oncology.

Alexis Borisy

Founding Investor and Board Member

Mark A. Goldsmith

Founding President and CEO

Steve Kelsey

President of Research and Development

2 past transactions

EQRx

Acquisition in 2023
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Warp Drive Bio

Acquisition in 2018
Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing genomic technology to discover drugs of natural origin. Founded in 2010, the company utilizes a proprietary genomic search engine and customized search queries to uncover hidden natural products by analyzing their unique genomic signatures. This innovative approach allows researchers to generate novel drug candidates and understand their mechanisms of action, facilitating the conversion of genomic data into potential therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.